KISS Communications announced today its merger with digital agency Isle Interactive, adding
significant resources and strengthening its position as a leading creative agency.
The merger gives the award-winning agency the foundation to achieve its ambitious growth plans and
broaden and strengthen its offer across marketing and brand strategy, campaign development, inmarket
activation and digital delivery – with creativity at its heart.
The newly combined team will add even more value and expertise to the agency’s blue-chip national
and international clients operating within the science,…
Prof. Claire Thompson, multi award-winning CEO of Agility Life Sciences, has been recognised as one of the Top 10 Leaders in the field of small molecules on the 2022 Medicine Maker Power List.
Every year, leading life sciences publication the Medicine Maker asks its readers to nominate the influential people making the most impact in the drug-making space, celebrating captains in small molecules, biopharmaceuticals, and advanced therapy. The aim of the Power List is to bring the talent, passion and experience of these inspirational leaders into the limelight, showcasing the drug development…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL PHARMACEUTICAL COMPANY
Development of stable injectable high concentration formulations for its proprietary products
Cambridge, UK, 16 June 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a top five global pharmaceutical company.
Under the terms of the agreement, Arecor will use its proprietary formulation technology…
Leading contract research organisation (CRO) Cellomatics Biosciences has moved into new purpose-built premises in Nottingham in the wake of rising demand for its bespoke preclinical and early drug discovery phase laboratory services.
The company’s new facilities in Colwick, Nottingham represent a three-fold increase in the company’s footprint, allowing room for further expansion. The purpose-built facility is an independent building covering approximately 5,500 sq ft of space across two levels. The ground floor is dedicated to laboratory facilities, whilst the first floor provides scientific…
The ‘Invest USA’ events program is the launch pad that supports UK & European companies seeking to invest in the USA.
We assist in gaining direct access to the right independent advisors and partners to successfully enter the USA. We take out the hassle and support you every step of the way for sustainable success. A trusted, experienced team to assist you through your USA journey.
Each brief we receive is treated as a bespoke solution and our deliverables are customised
and tailored to your needs.
The Invest USA program covers services such as;
Board…
Cambridge, UK, 13 June 2022:
EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Colin McCracken as Chief Executive Officer with immediate effect. Colin’s appointment will support the next phase of the Company’s development and the commercialisation of its semiconductor-based DNA synthesis platform.
Colin brings over 20 years’ experience in commercial and business development roles. Prior to joining Evonetix he was Senior Vice President and Chief Commercial Officer at Fluidigm Corp, where…
Analysis Published by PrecisionLife Reveals Potential to Systematically Reposition Hundreds of Patented Drugs into New Indications to Address Unmet Medical Needs
• PrecisionLife’s unique combinatorial analytics approach to understanding the drivers of disease biology in patient subgroups has revealed hundreds of new commercial opportunities to reposition patented drugs and drug candidates into novel indications, with significant near-term additional revenue potential for pharmaceutical companies
• Careful indication extension or repositioning of drugs coupled with patient stratification…
AMSBIO has expanded its range of top quality, high-performance assay kits, antibodies, enzymes, and substrates for cellular metabolism research.
Cell metabolism is the series of chemical synthesis (Anabolism) and degradation (Catabolism) reactions of complex macromolecules, catalyzed by enzymes that take place in living organisms to sustain those organisms. Anabolism uses energy to make macromolecules (sugars, fatty acids, amino acids) and biomolecular polymers (polysaccharides, lipids, proteins). Catabolism releases energy when these are broken down into smaller molecules (carbon dioxide,…
The Enterprise Strategy from Anglia Innovation Partnership LLP will kickstart investment into new businesses at Norwich Research Park.
Anglia Innovation Partnership LLP, the organisation that manages Norwich Research Park, has launched its Enterprise Strategy to kickstart investment into new businesses at the Park.
Its aim is two-fold: to encourage those with a potential idea for a business – be they entrepreneurs or people studying or working at the Park – to come forward for support. It will also highlight to investors – whether venture capital companies or high net worth individuals – the…
Presenters will explain how long-term and whole-cell hepatocyte models can be used to improve in-vitro in-vivo correlation predictions and advance drug discovery and development research
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it will host a symposium entitled “Innovative Models for ADME-Tox Research” at Hotel Odelya in Basel, Switzerland on June 22.
“We are delighted to have this opportunity to meet with our biopharmaceutical colleagues in person,” said Jeremy Clarke, Senior Director of Business…